Recent Transactions

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

19-Aug-22
$2.2 billion
United States flag
Target: 

GI Alliance

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

09-Feb-21
Undisclosed
United States flag
Target: 

US Acute Care Solutions

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson

01-Oct-20
$1.05 billion
United States flag
Target: 

Akorn, Inc.

flag not available
Acquiror: 
First Lien Term Loan Lenders

Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

show all